Xenon Pharmaceuticals Inc. (XENE)
收市後：
Xenon Pharmaceuticals Inc.
3650 Gilmore Way
Suite 200
Burnaby, BC V5G 4W8
Canada
604 484 3300
https://www.xenon-pharma.com
版塊: Healthcare
行業: Biotechnology
全職員工: 251
高階主管
| 名稱 | 頭銜 | 支付 | 行使價 | 出生年份 |
|---|---|---|---|---|
| Mr. Ian C. Mortimer C.M.A., CPA, M.B.A. | President, CEO & Director | 1.07百萬 | 2.37百萬 | 1976 |
| Ms. Sherry Aulin C.A., CPA | Chief Financial Officer | 664.8千 | 無 | 1983 |
| Dr. Robin P. Sherrington Ph.D. | Executive Vice President of Strategy & Innovation | 587.03千 | 無 | 1961 |
| Dr. Christopher E. Von Seggern M.B.A., M.P.H., M.P.H. M.B.A, Ph.D. | Chief Commercial Officer | 621.12千 | 無 | 1979 |
| Dr. Christopher John Kenney M.D. | Chief Medical Officer | 719.82千 | 無 | 1971 |
| Ms. Andrea DiFabio J.D. | Chief Legal Officer & Corporate Secretary | 200.51千 | 無 | 1968 |
| Ms. Shelley McCloskey B.A. | Executive Vice President of Human Resources | 無 | 無 | 1960 |
| Dr. James R. Empfield Ph.D. | Executive Vice President of Drug Discovery | 323.43千 | 無 | 1961 |
| Ms. Sheila M. Grant M.B.A., M.Sc., MBA | Executive Vice President of R&D Operations | 無 | 無 | 無 |
描述
Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.
公司管治
截至 無 止，Xenon Pharmaceuticals Inc. 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。
